Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of IDN-6556 in Hepatic Impairment
NCT02121860Phase 1Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emricasan in liver failure (4 arms), sponsored by Conatus Pharmaceuticals Inc. Primary endpoints: Area Under the Curve at 48 Hours and Maximum Plasma Concentration at 48 Hours. Started Apr 2014; status: completed.
02
Drugs
emricasan
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT02121860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121860.